Correlation Between Fresh Tracks and Salarius Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Fresh Tracks and Salarius Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Fresh Tracks and Salarius Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Fresh Tracks Therapeutics and Salarius Pharmaceuticals, you can compare the effects of market volatilities on Fresh Tracks and Salarius Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Fresh Tracks with a short position of Salarius Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Fresh Tracks and Salarius Pharmaceuticals.

Diversification Opportunities for Fresh Tracks and Salarius Pharmaceuticals

0.07
  Correlation Coefficient

Significant diversification

The 3 months correlation between Fresh and Salarius is 0.07. Overlapping area represents the amount of risk that can be diversified away by holding Fresh Tracks Therapeutics and Salarius Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Salarius Pharmaceuticals and Fresh Tracks is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Fresh Tracks Therapeutics are associated (or correlated) with Salarius Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Salarius Pharmaceuticals has no effect on the direction of Fresh Tracks i.e., Fresh Tracks and Salarius Pharmaceuticals go up and down completely randomly.

Pair Corralation between Fresh Tracks and Salarius Pharmaceuticals

Given the investment horizon of 90 days Fresh Tracks Therapeutics is expected to generate 1.33 times more return on investment than Salarius Pharmaceuticals. However, Fresh Tracks is 1.33 times more volatile than Salarius Pharmaceuticals. It trades about 0.13 of its potential returns per unit of risk. Salarius Pharmaceuticals is currently generating about -0.04 per unit of risk. If you would invest  59.00  in Fresh Tracks Therapeutics on August 31, 2024 and sell it today you would earn a total of  19.00  from holding Fresh Tracks Therapeutics or generate 32.2% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy8.56%
ValuesDaily Returns

Fresh Tracks Therapeutics  vs.  Salarius Pharmaceuticals

 Performance 
       Timeline  
Fresh Tracks Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Fresh Tracks Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Fresh Tracks is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
Salarius Pharmaceuticals 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Salarius Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Salarius Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Fresh Tracks and Salarius Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Fresh Tracks and Salarius Pharmaceuticals

The main advantage of trading using opposite Fresh Tracks and Salarius Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Fresh Tracks position performs unexpectedly, Salarius Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Salarius Pharmaceuticals will offset losses from the drop in Salarius Pharmaceuticals' long position.
The idea behind Fresh Tracks Therapeutics and Salarius Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Complementary Tools

Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance